Crysvita (burosumab)

Context: Rare bone disorders including XLH and TIO; post-launch patient programs and longitudinal observation.

Evidence: $87.3M (2019) → $410.0M (2024).

Role BEYONDXLH Phase IV Lead in partnership with Yale School of Medicine and the XLH Network; patient experience design and longitudinal data capture.